

NFL BIOSCIENCES: FINANCIAL CALENDAR FOR 2024

NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, presents its financial communication calendar for 2024.

Subject	Date*
2023 annual results	March 29 th 2024
Annual General Meeting (Montpellier)	May 30 th 2024
2024 half-year results	September 27 th 2024

*Press releases will be published after the close of the stock market

The calendar is provided for information purposes only and may be subject to modification

About NFL Biosciences

NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.

The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com

Contacts

Bruno Lafont – info@nflbiosciences.com - 04 11 93 76 67

Agence Calyptus – nflbio@calyptus.net - 01 53 65 68 68